

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Complete if Known

Application Number	10/652,814
Filing Date	August 29, 2003
First Named Inventor	Unger
Art Unit	1636
Examiner Name	Riggins, P.
Attorney Docket Number	3193.01US03

1 of 2

U.S. PATENT DOCUMENTS

EXAMINER INITIAL ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number-Kind Code ² (if known)		
IP		US-5,492,814	02-20-1996	Weissleder
IP		US-6,255,457	07-03-2001	Schnitzer
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	1 ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
IP		WO 99/29349	06-17-1999	Behr et al.	

EXAMINER
SIGNATURE

/Ileana Popa/

DATE
CONSIDERED

06/02/2006

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/652,814
				Filing Date	August 29, 2003
				First Named Inventor	Unger
				Art Unit	1636
				Examiner Name	Riggins, P.
Sheet	2	of	2	Attorney Docket Number	3193.01US03

NON PATENT LITERATURE DOCUMENTS


EXAMINER INITIAL ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
IP		ANDERSON, "The Caveolae Membrane System", <u>Ann. Rev. Biochem.</u> , 67:199-225 (1998).	
IP		FENG ET AL., "Vesiculo-Vacuolar Organelles and the Regulation of Venule Permeability to Macromolecules by Vascular Permeability Factor, Histamine, and Serotonin", <u>J. Exp. Med.</u> , 183:1981-1986 (1996).	
IP		VARGA ET AL., "Receptor-mediated Targeting of Gene Delivery Vectors; Insights from Molecular Mechanisms for Improved Vehicle Design", <u>Biotechnology and Bioengineering</u> , 70(6): 593-605 (2000).	

EXAMINER SIGNATURE	/Ileana Popa/	DATE CONSIDERED	06/02/2006
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/652,814
Filing Date	August 29, 2003
First Named Inventor	Unger
Art Unit	1636
Examiner Name	Unknown
Attorney Docket Number	3193.01US03

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIAL [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
IP		AL-MOUSA, ET. AL, (1999) J Pharm Pharmacol 51(supplement):178, "Evidence for the role of caveolae in gene delivery."	
IP		LEWIN ET. AL, (2000) Nature 18:410-414, "Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells."	
IP		MATVEEV ET. AL, (2001) Adv Drug Deliv Rev 49:237-250, "The role of caveolae and caveolin in vesicle-dependent and vesicle-independent trafficking."	
IP		WOLFF ET. AL, (1992) J Cell Sci 103:1249-59, "Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle."	

EXAMINER
SIGNATURE

/Ileana Popa/


DATE
CONSIDERED

06/02/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/652,814	
				Filing Date	August 29, 2003	
				First Named Inventor	Unger	
				Art Unit	1636	
				Examiner Name	Unknown	
Sheet	1	of	8	Attorney Docket Number	3193.01US03	
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL [*]	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
		Number-Kind Code ² (if known)				
IP		US-4,107,288	08-15-1978	Oppenheim et al.		
		US-4,177,177	12-04-1979	Vanderhoff et al.		
		US-4,913,908	04-03-1990	Couvreur et al.		
		US-4,920,016	04-24-1990	Allen et al.		
		US-4,937,119	06-26-1990	Nikles et al.		
		US-4,968,350	11-06-1990	Bindschaedler et al.		
		US-5,116,507	05-14-1996	N'Guyen et al.		
		US-5,133,908	07-28-1992	Stainmesse et al.		
		US-5,145,684	09-08-1992	Liversidge et al.		
		US-5,384,133	01-24-1995	Boyes et al.		
		US-5,439,686	08-08-1995	Desai et al.		
		US-5,498,421	03-12-1996	Grinstaff et al.		
		US-5,503,851	04-02-1996	Mank et al.		
		US-5,578,709	11-26-1996	Woiszwilllo		
		US-5,629,021	05-13-1997	Wright		
		US-5,639,473	06-17-1997	Grinstaff et al.		
		US-5,639,480	06-17-1997	Bodmer et al.		
	IP		US-5,648,095	07-15-1997	Illum et al.	
	FOREIGN PATENT DOCUMENTS					
EXAMINER INITIAL [*]	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
IP		EP0860167	08-26-1998	Gurny		
IP		WO00/47130	08-17-2000	Devore		
IP		WO88/08011	10-20-1988	Bindschaedler et al.		
IP		WO97/03702	02-06-1997	Mathiowitz et al.		
EXAMINER SIGNATURE		/Ileana Popa/		DATE CONSIDERED	06/02/2006	
<small>[*]EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</small>						

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/652,814
				Filing Date	August 29, 2003
				First Named Inventor	Unger
				Art Unit	1636
				Examiner Name	Unknown
Sheet	2	of	8	Attorney Docket Number	3193.01US03
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL [*]	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		Number-Kind Code ² (if known)			
IP		US-5,648,097	07-15-1997	Nuwayser	
		US-5,736,156	07-07-1998	Burke	
		US-5,759,582	06-02-1998	Leong et al.	
		US-5,846,561	12-08-1998	Margalit	
		US-5,858,398	01-12-1999	Cho	
		US-5,874,111	02-23-1999	Maitra et al.	
		US-5,916,803	06-29-1999	Sedlacek et al.	
		US-5,962,427	10-05-1999	Goldstein et al.	
		US-5,962,566	10-05-1999	Grandfils et al.	
		US-5,985,832	11-16-1999	Roodman et al.	
		US-5,990,089	11-23-1999	Szoka Jr. et al.	
		US-6,033,645	03-07-2000	Unger	
		US-6,051,258	04-18-2000	Kantor	
		US-6,136,295	10-24-2000	Edwards et al.	
		US-6,139,870	10-31-2000	Verrecchia	
		US-6,143,037	11-07-2000	Goldstein et al.	
		US-6,143,211	11-07-2000	Mathiowitz et al.	
		US-6,146,663	11-14-2000	Bissery et al.	
	IP		US-6,165,440	12-26-2000	Esenaliev
FOREIGN PATENT DOCUMENTS					
EXAMINER INITIAL [*]	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
IP		WO98/43664	10-08-1998	Kim et al.	
IP		WO99/00113	01-07-1999	Desai et al.	
IP		WO99/33558	07-08-1999	Quintanar-Guerrero et al.	
EXAMINER SIGNATURE		/Ileana Popa/		DATE CONSIDERED	06/02/2006
<small> [*]EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450. </small>					

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/652,814
				Filing Date	August 29, 2003
				First Named Inventor	Unger
				Art Unit	1636
				Examiner Name	Unknown
Sheet	3	of	8	Attorney Docket Number	3193.01US03
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		Number-Kind Code ² (if known)			
IP		US-6,165,988	12-26-2000	Noe et al.	
IP		US-6,177,103	01-23-2001	Pace et al.	
IP		US-6,197,346	03-06-2001	Mathiowitz et al.	
IP		US-6,322,805	11-27-2001	Kim et al.	
IP		US-6,322,805	11-27-2001	Kim et al.	
IP		US-6,372,714	04-16-2002	Tanaka et al.	
IP		US-6,632,671	10-14-2003	Unger	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
FOREIGN PATENT DOCUMENTS					
EXAMINER INITIAL*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
EXAMINER SIGNATURE		/Ileana Popa/		DATE CONSIDERED	06/02/2006
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</small>					

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/652,814
				Filing Date	August 29, 2003
				First Named Inventor	Unger
				Art Unit	1636
				Examiner Name	Unknown
Sheet	4	of	8	Attorney Docket Number 3193.01US03	
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
IP		AKHTAR, ET AL., (2000): The delivery of antisense therapeutics. Advanced Drug Delivery Reviews (44): 3-21.			
		ASH, ET AL., Handbook of Industrial Surfactants, Gower Publishing Co. (1993), pp. 885-905.			
		BALLY ET AL., (1999): Biological barriers to cellular delivery of lipid-based DNA carriers, Advanced Drug Delivery Reviews (38):291-315.			
		BARRY, B. W., Dermatological Formulations: Percutaneous Absorption, pages 127-531.			
		BRAND ET AL., (2000): Transdermal delivery of antisense compounds. Advanced Drug Delivery Reviews (44) 51-57.			
		BRANNON-PEPPAS (1997): Polymers in Controlled Drug Delivery. Medical Plastics and Biomaterials Magazine: 1-17.			
		BRONAUGH, ET AL., Editors, Percutaneous Absorption Drugs-Cosmetics-Mechanisms-Methodology, 3rd Ed., (1999), pp. 177-193; 597-613 and 879-886.			
		CALVO, ET AL., Comparative in vitro Evaluation of Several Colloidal Systems, Nanoparticles, Nanocapsules, and Nanoemulsions, as Ocular Drug Carriers, Journal of Pharmaceutical Sciences, (1995), pp. 530-536.			
		CALVO, ET AL, Evaluation of Cationic Polymer-Coated Nanocapsules as Ocular Drug Carriers, International Journal of Pharmaceutics (1997), pp. 41-50.			
		DAMAGE ET AL., Intestinal Absorption of PLAGA microspheres in the rat, (1996) J. Anat, pp. 491-501.			
		DEAN, Lange's Handbook of Chemistry, 15th Edition, pages 1.74-1.343, 10.69-10.73.			
IP		DOKKA ET AL., (2000): Novel non-endocytic delivery of antisense oligonucleotides, Advanced Drug Delivery Reviews (44): 35-49.			
EXAMINER SIGNATURE		/Ileana Popa/		DATE CONSIDERED	06/02/2006
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p> <p style="text-align: center;"><i>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</i></p>					

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/652,814
				Filing Date	August 29, 2003
				First Named Inventor	Unger
				Art Unit	1636
				Examiner Name	Unknown
Sheet	5	of	8	Attorney Docket Number	3193.01US03
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
IP		GAUR ET AL., (2000): Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system, International Journal of Pharmaceutics (2002):1-10.			
		GENNARO, Remington: The Science and Practice of Pharmacy, 20th Ed., Lippincott Williams & Wilkins, pp. 288-334; 721-752; 836-857 and 903-929.			
		GERNER ET AL., (1998): Similarity Between Nuclear Matrix Proteins of Various Cells Revealed by an Improved Isolation Method. Journal of Cellular Biochemistry (71) 363-374.			
		GOLAN ET AL., (1999): DNA Toroids: Stages in Condensation. Biochemistry (38): 14069-14076.			
		GOPFERICH, (1995): Polymer Degradation and Erosion: Mechanisms and Applications. Eur. J. Pharm. Biophar. 42(1):1-11.			
		JANES, ET AL., Polysaccharide Colloidal Particles as Delivery Systems for Macromolecules, Advanced Drug Delivery Reviews (2001), pp. 83-97.			
		KATOAKA, ET AL., Block Copolymer Micelles for Drug Delivery: Design, Characterization and Biological Significance, Advanced Drug Delivery Reviews (2001), pp. 113-131.			
		KAWASHIMA, Nanoparticle Systems for Improved Drug Delivery, Advanced Drug Delivery Reviews (2001), pp. 1-2.			
		KIBBE, ARTHUR H. EDITOR, (1986): Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, Third Edition, pages 94-95, 117-120.			
		KREUTER, Mini-review: Nanoparticles and Microparticles for Drug and Vaccine Delivery, J. Anat. (1996), pp. 503-505.			
		GOLAN ET AL., (1999): DNA Toroids: Stages in Condensation. Biochemistry (38): 14069-14076.			
IP		GOPFERICH, (1995): Polymer Degradation and Erosion: Mechanisms and Applications. Eur. J. Pharm. Biophar. 42(1):1-11.			
EXAMINER SIGNATURE	/Ileana Popa/			DATE CONSIDERED	06/02/2006
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p> <p><i>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</i></p>					

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/652,814
				Filing Date	August 29, 2003
				First Named Inventor	Unger
				Art Unit	1636
				Examiner Name	Unknown
Sheet	6	of	8	Attorney Docket Number	3193.01 US03
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
IP		JANES, ET AL., Polysaccharide Colloidal Particles as Delivery Systems for Macromolecules, Advanced Drug Delivery Reviews (2001), pp. 83-97.			
		KATOAKA, ET AL., Block Copolymer Micelles for Drug Delivery: Design, Characterization and Biological Significance, Advanced Drug Delviery Reviews (2001), pp. 113-131.			
		KAWASHIMA, Nanoparticle Systems for Improved Drug Delivery, Advanced Drug Delivery Reviews (2001), pp. 1-2.			
		KIBBE, ARTHUR H. EDITOR, (1986): Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, Third Edition, pages 94-95, 117-120.			
		KREUTER, Mini-review: Nanoparticles and Microparticles for Drug and Vaccine Delivery, J. Anat. (1996), pp. 503-505.			
		KREUTER, Nanoparticulate Systems for Brain Delivery of Drugs, Advanced Drug dleivery Reviews (2001), pp. 65-81.			
		KREUTER, Nanopaticles-Preparation and Applications, Microcapsules and Nanoparticles in Medicine and Pharmacy, pp. 125-148.			
		KREUTER, Nanopatricle-Based Drug Delivery Systems, Journal of Controlled Release (19914), pp. 169-176.			
		LAMAZE, ET AL., The Emergence of Clathrin-Independnet Pinocytic Pathways, Current Opinion in Cell Biology (1995), pp. 573-580.			
		LI ET AL., (2000): Nonviral gene therapy: promises and challenges, Gene Therapy (7): 31-34.			
		LIBERMAN, ET AL., (1996): Pharmaceutical Dosage Forms: Disperse Systems, Vol. 2, Second Edition, pages 1-109.			
IP		LIDE, EDITOR IN CHIEF, CRC Handbook of Chemistry and Physics: A Ready-Reference Book of Chemical and Physical Data, Chemical Rubber Publishing Co, 81st, (1922), pp. 7-7 to 7-9; 16-10 to 16-11; 16-43 to 16-47; Appendix.			
EXAMINER SIGNATURE		/Ileana Popa/		DATE CONSIDERED	06/02/2006
<p>¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p> <p style="text-align: center;">If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</p>					

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/652,814
				Filing Date	August 29, 2003
				First Named Inventor	Unger
				Art Unit	1636
				Examiner Name	Unknown
Sheet	7	of	8	Attorney Docket Number 3193.01US03	
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
IP		MODLIN, (2000): A toll fro DNA vaccines. Nature (408): 659-660.			
		MULLER ET AL., Nanosuspensions as Particulae Drug Formulations in Therapy Rationale for Development and What We Can Expect for the Future, Advanced Drug Delviery Reviews (2001), pp. 3-19.			
		NISHIOKA ET AL., Lymphatic Targeting with Nanoparticulate System, Advanced Drug Delivery Reviews (2001), pp. 55-64.			
		NOONBERG, ET AL., (1993): Characteristics of Oligonucleotide Uptake in Human Keratinocyte Cultures. The Jouranal of Invenstigative Dermatology (101): 727-731.			
		Perry's Chemical Engineers' Handbook, (1934), 7th Ed. pp. 2-24 to 2-47.			
		PINTO, ET AL., Pellets as carriers of solid lipid nanoparticles (SLN) for oral administration of Drugs, Pharmazie (1999), pp. 506-509.			
		QUINTANAR-GUERRERO ET AL., (1998): Preparation Techniques and Mechanisms of Formation of Biodegradable Nanoparticles from Performed Polymers. Drug Development and Industrial Pharmacy, 24(12): 1113-1128.			
		ROLLAND, (1998): From Genes to Gene Medicines: Recent Advances in Nonviral Gene Delivery. Critical Reviews in Tsherapeutic Drug Carrier Systems 15(2):143-198.			
		SAKUMA ET AL., Design of Nanoparticles Composed of Graft Copolymers for Oral Peptide Delivery, Advanced Drug Delivery Reviews (2001), pp. 21-37.			
		SCHMIDT, ET AL., Incorporation of Polymeric Nanoparticles into Solid Dosage Forms, Journal of Controlled Release (1997), pp. 115-125.			
		Sigma Company Catalog, Sigma Biochemical and Reagents For Life Science Research, St. Louis, MO. p 1918.			
IP		SMITH, ET AL, Percutaneous Penetration Enhancers, (1995), pp. 1-20.			
EXAMINER SIGNATURE		/Ileana Popa/		DATE CONSIDERED	06/02/2006
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p> <p style="text-align: center;"><i>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</i></p>					

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/652,814
				Filing Date	August 29, 2003
				First Named Inventor	Unger
				Art Unit	1636
				Examiner Name	Unknown
Sheet	8	of	8	Attorney Docket Number	3193.01US03
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
IP		TAKEUCHI ET AL., Mucoadhesive Nanoparticle Systems for Peptide Drug Delivery, Advanced Drug Delivery Reviews (2001), pp. 39-54.			
IP		VILE, ET AL., Millenium Review: Cancer Gene Therapy: Hard Lessons and New Courses, Gene Therapy, pp. 2-8.			
IP		YUAN ET AL., (1994): Microvascular Permeability and Interstitial Penetration of Sterically Stabilized (stealth) Liposomes in a Human Tumor Xenograft. Cancer Research (54) 3352-3356.			
IP		ZHANG ET AL., (1997): Comparison of Integrins in Human Skin, Pig Skin, and Perfused Skin: An In Vitro Skin Toxicology Model. Journal of Applied Toxicology 17(4): 247-253.			
EXAMINER SIGNATURE	/Ileana Popa/			DATE CONSIDERED	06/02/2006
<p><small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</small></p> <p><small>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</small></p> <p style="text-align: center;"><i>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</i></p>					